Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma. Meeting Abstract

cited authors

  • Jain, Rohit K.; Yang, Yuanquan (Aaron); Chadha, Juskaran; Zhang, Jingsong; Raymond, Sarah; Oschmann, Erika; Poehlman, Trey; Fan, Wenyi; Kim, Youngchul; Dhillon, Jasreman; Chahoud, Jad; Chatwal, Monica Sheila; Sonpavde, Guru P.

Publication Date

  • February 1, 2024

webpage

published in

category

keywords

  • 1
  • 130-540-543-4790
  • 14
  • 1876
  • 2
  • 283-183-138-11076
  • 298-145-222-184-1022-9124
  • 298-145-222-2710
  • 3
  • 3581
  • 38092-27449
  • 47
  • 5
  • 613-135-2370-7650-2700
  • 613-135-244-3829-325
  • 613-225-3248-9559-9794
  • 62

start page

  • TPS713

end page

  • TPS713

volume

  • 42

issue

  • 4_SUPPL